Nucleic acid vaccines have arrived with unprecedented speed and impact. We make them even better.

Introducing Orlance MACH-1®

LOW-DOSE, HIGHLY SCALABLE POWDERED NUCLEIC ACID VACCINES WITHOUT COLD CHAIN REQUIREMENTS.

Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions.  Leveraging $9.6M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance.  The company’s executive team comprises significant immunology, vaccinology, biotech development, bioengineering, regulatory, and partnering experience and is well poised to bring its preclinical assets to IND and Phase 1 readiness in 2022.

Meet Us At:

Boston Biotech Week, Sept 20-23, 2021

World Vaccine Congress Europe, Oct 19-21, 2021

Our Team

Orlance, inc

Kris Aalto, CEO

25 years of bioengineering, innovation development, regulatory and clinical affairs, product launch, VC and executive experience.

Deb Fuller, PhD, CTO

Co-inventor of MACH-1 technology, formerly at PowderJect, UW Professor, the lab focuses on NA vaccines for multiple pathogens.

Jim Mullins, PhD

Co-founder and SAB member, UW, molecular and computational approaches vaccine design, the originator of conserved element (CE) approach to vaccine development.

Ken Bagley, PhD

DIR. R&D 15 years in NA vaccine field, developed genetic adjuvant platform at Profectus Biosciences, Inc.

Hannah Frizzell, PhD

Bioengineer, Immunology, and nano delivery system experience.

Lyuda Lebedinski

Administrative and
Financial Manager

Amanda Woodcock

Mechanical Engineer

Jonathan Aalto

Research Technician

IF YOU’RE A POTENTIAL PARTNER

Series A or government funding for Phase 1/2a Orlance MACH-1® influenza or CoV vaccine

DNA and mRNA vaccine Phase 1 candidates

Kristyn Aalto, CEO

206-792-5069

kaalto@orlance.com

© 2021 Orlance Inc. | Site by Malolo Design